protease that is responsible for the majority of A␤ degraAlthough the amyloid hypothesis (more correctly, the dation may be elusive. Indeed, there is already evidence A␤ hypothesis) for the causation of Alzheimer's disease that several enzymes may contribute to the degradation (AD) still stirs strong passions, the number of genetic, of A␤ peptides in brain tissue (Table 1) . At the outset, biochemical, and animal modeling studies supporting one must distinguish between proteases that appear to its validity is impressive and growing apace. But proof degrade A␤ only in its monomeric state and those that can only come from successful trials of A␤-lowering can degrade oligomeric and/or highly aggregated (fibriltherapies in humans. Happily, this process has recently lar) forms of the peptide. Very few examples of the latter begun.
robust effect than that of deleting just neprilysin. An interpretation that could explain the existing data K. Vekrellis and D.J.S., unpublished data), confirmation of the effects of this protease in vivo, e.g., in mice lacking on both IDE and neprilysin is that IDE mediates much of the degradation of soluble, monomeric A␤ but has the IDE gene, is now required.
The intracerebral injection of synthetic A␤ peptides less ability to degrade A␤ once it becomes insoluble and/or oligomeric, whereas neprilysin has little role in in the presence or absence of various protease inhibitors provided evidence that neprilysin is a major A␤ 42 -degraddegrading soluble A␤ but can degrade buffer-insoluble, SDS-extractable A␤ associated with membranes. Coning protease in rat brain, although the enzyme did not mediate A␤ 40 ., 2000) . Moreover, tures, mice, and human brain tissue reviewed above suggest that specific neural proteases actively degrade this in vitro effect may not predict similar activity on amyloid fibrils in vivo, because serum amyloid P compo-A␤ monomers under physiological conditions. Therefore, inherited or acquired defects in A␤-degrading pronent, which is associated with amyloid deposits in AD brain, is able to bind to and prevent the proteolysis of teases could chronically elevate A␤ levels in a manner mechanistically distinct from but quantitatively similar isolated cerebral amyloid (Tennent et al., 1995) . Evidence for a role of plasmin in regulating A␤ monomer to presenilin mutations. In attempts to date to implicate A␤ proteases in familial AD, early work is pointing to IDE or polymer levels in vivo has not yet appeared.
Another protease expressed in brain that has been and uPA as candidate genes. Both genes are located on chromosome 10q, and different sets of late-onset AD evaluated for its ability to degrade A␤ is endothelin con- In separate experiments, an apparently distinct linkage region has been localized to chromosome10q, and Gibson, 1996).
